Why Ardelyx Is Soaring Today

What happened

After upbeat results from a Phase 3 trial, shares of Ardelyx (NASDAQ: ARDX), a clinical-stage biotech focused on cardiorenal disease, rose as much as 23% in early-morning trading on Tuesday. Shares were up about 16% as of 10:37 a.m. EDT.

So what

Ardelyx reported positive results from its Phase 3 AMPLIFY study today. This trial was designed to test its experimental drug tenapanor in combination with phosphate binders as a hopeful treatment for patients with chronic kidney disease who are on dialysis.

Here are the key takeaways from the study:

  • Tenapanor met the study's primary endpoint and all key secondary endpoints.
  • Patients who received tenapanor showed a statistically significant (p = 0.0004) mean reduction in serum phosphorus from baseline of 0.84 mg/dL at the end of four weeks. That was much better than the control group, which showed a mean reduction of just 0.19 mg/dL.
  • Up to 49.1% of patients in the tenapanor group achieved a serum phosphorus of < 5.5 mg/dL. That compares favorably to a 23.5% result in the control group.
  • Patients in the tenapanor group showed a statistically significant 22% to 24% reduction in FGF23 levels when compared to the control group. That's important because elevated levels of FGF23 are associated with an increased risk of major cardiovascular events.
  • Tenapanor was well tolerated, with a 4.3% discontinuation rate. That compares to 2.5% in the control group.
  • There were no serious adverse events related to tenapanor.
Female doctor giving thumbs-up signal.

Image source: Getty Images.

Ardelyx's CEO Mike Raab was happy with the results:

We are thrilled with the positive results from the AMPLIFY study demonstrating that tenapanor can help significantly more patients achieve the established serum phosphorus treatment goal of less than 5.5 mg/dL. This result is striking as serum phosphorus levels above 5.5 mg/dL are associated with increased mortality. For too long, hyperphosphatemia management has been an enormous challenge for patients and clinicians. With tenapanor, patients may finally be able to achieve their treatment goal.

Traders are bidding up the stock in response to the encouraging clinical results.

Now what

Ardelyx is currently running another Phase 3 study called PHREEDOM that is testing tenapanor as a monotherapy. The company expects to share results from that trial in the fourth quarter. Once the PHREEDOM trial is complete, management plans to submit tenapanor for regulatory approval in monotherapy and combination therapy for the treatment of hyperphosphatemia.

Investing in biotech stocks can be risky, especially when the company is still in the clinical stage. However, Ardelyx could be on the cusp of becoming a commercial business, because tenapanor is currently pending FDA approval as a potential treatment for irritable bowel syndrome with constipation. A go/no go decision is expected to be handed down by Sept. 12, 2019, so investors won't have to wait long to learn more.

The back half of 2019 should be an exciting time for Ardelyx's investors. This Fool plans on following this company's progress with great interest.

10 stocks we like better than Ardelyx
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has quadrupled the market.*

David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Ardelyx wasn't one of them! That's right -- they think these 10 stocks are even better buys.

See the 10 stocks


*Stock Advisor returns as of June 1, 2019


Brian Feroldi has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story


Latest Markets Videos

The Motley Fool

Founded in 1993 in Alexandria, VA., by brothers David and Tom Gardner, The Motley Fool is a multimedia financial-services company dedicated to building the world's greatest investment community. Reaching millions of people each month through its website, books, newspaper column, radio show, television appearances, and subscription newsletter services, The Motley Fool champions shareholder values and advocates tirelessly for the individual investor. The company's name was taken from Shakespeare, whose wise fools both instructed and amused, and could speak the truth to the king -- without getting their heads lopped off.

Learn More